background: Identification of new markers assessing endometrial receptivity may help in improving the clinical outcome of IVF. This study aimed at identifying genes expressed in human endometrium during the implantation window that could be used as such markers.
Introduction
Despite many advances in assisted reproduction techniques, implantation rates are still low after controlled ovarian stimulation and IVF (Donaghay and Lessey, 2007) . Implantation failure is thought to result from impairment of embryo development and/or from abnormal uterine receptivity. The endometrium is receptive to blastocyst implantation during a spatially and temporally restricted window, called 'the implantation window' (Paria et al., 2000) . In humans, this period begins 6-10 days after the LH surge and lasts 48 h (Wilcox et al., 1999; Martin et al., 2002) .
Successful implantation depends on synchronization between the developmental stages of the embryo itself and the complex series of molecular and cellular events induced in the endometrium by paracrine and autocrine regulators during the implantation window (Davis and Senger, 2005; Bischof and Campana, 2000) . This suggests that many molecular markers will be candidates to determine the 'ideal' endometrial receptive period (Abate et al., 1987; van der Gaast et al., 2003; Horcajadas et al., 2004; Edwards, 2006; Aghajanova et al., 2008) . Several approaches have been used to identify these biomarkers, such as endometrium biopsy examination, endometrium ultrasonography, and blood and uterine fluid analysis (Abate et al., 1987; van der Gaast et al., 2003; Aghajanova et al., 2008; Dechaud et al., 2008) . More recently, transcriptomic approaches have been used to identify biomarkers of the human implantation window. Using microarray technology in human biopsy samples, several authors have observed modifications in gene expression profile associated with the transition of the human endometrium from a prereceptive (early secretory phase) to a receptive (mid-secretory phase) state (Carson et al., 2002; Riesewijk et al., 2003; Mirkin et al., 2005; Talbi et al., 2006) . However, among the various regulated genes, very few were in common between all these studies. Such variability in the results with the same approach may have several explanations: varying mRNA quantities from endometrium cells, different patient profiles and/or limited patient samples (n 11). In addition, only one study compared the early and the mid-secretory phase in the same patient (Riesewijk et al., 2003) , which seems to us a necessary condition to minimize the impact of inter-patient variability.
Therefore, in this study, we revisited the global gene expression profile of human endometrial biopsies by using a larger series of patients (n ¼ 31) and samples (n ¼ 62) that were collected during the early secretory phase, 2 days after the LH surge (LH þ 2) and the mid-secretory phase (LH þ 7) of a natural menstrual cycle.
Materials and Methods

Patient characteristics and endometrial biopsies
This project has received institutional review board approval. The study population included 31 patients (mean + SEM age: 30.4 + 3.2 years), recruited after written informed consent. All patients had normal serum FSH, LH, estradiol (E 2 ) and anti-Müllerian hormone levels on Day 3 and were normoresponders during a previous first ICSI attempt. They were referred for ICSI for male infertility factor. Endometrial pathologies, such as endometriosis or tubal disease, were not explored by histological analysis. During the same natural cycle that preceded a second ICSI attempt, two endometrial biopsies were obtained in all women at Day 2 (LH þ 2) and Day 7 (LH þ 7) after the LH peak. The LH surge was estimated by patient herself according to the first day of their menstruation. Histologic analysis was not performed to verify that the LH timing was accurate. Therefore, the possibility for a delay of 1 day from the first day of menstruation cannot be excluded. Each biopsy sample was washed in phosphate-buffered saline and frozen at 2808C in RLT RNA extraction buffer (RNeasy kit, Qiagen, Valencia, CA, USA).
Complementary RNA preparation and microarray hybridization
Total RNA (100 ng) was used to prepare twice amplified labeled complementary RNA (cRNA) for hybridization to HG-U133 plus 2.0 GeneChip pangenomic oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA) as described in Assou et al. (2007) and Gasca et al. (2007) .
Microarray data analyses
HG-U133 plus 2.0 arrays contain 54 675 oligonucleotide probe sets, which correspond to 30 000 unique human genes or predicted genes. Array analysis was performed with the GeneChip Operating Software 1.2 (Affymetrix) to measure significant RNA detection (detection call 'present' or 'absent') and to evaluate the signal intensity for each probe set .
Bioinformatics and in silico analyses
The significant analysis of microarrays (SAM, Stanford University, USA, Tusher et al., 2001 ) was used to identify genes whose expression varied significantly between the two sample groups, LH þ 2 (n ¼ 31) and LH þ 7 (n ¼ 31). SAM provides mean or median fold change values and a false discovery rate (FDR) confidence percentage based on data permutation.
To compare profile expression of endometrial samples (n ¼ 62) from the LH þ 2 and LH þ 7 groups, we performed an unsupervised classification with both principal component analysis (PCA) and hierarchical clustering (Eisen et al., 1998; de Hoon et al., 2004) . The PCA involved original scripts based on the R-statistics software through the RAGE web interface (http://rage.montp.inserm.fr) (Rème et al., 2008) . Hierarchical clustering analyses based on the expression levels of varying probes were performed with the CLUSTER and TREEVIEW software packages. Genetic expression profiles were analyzed with the RAGE supervised analysis module, using a non-parametric Mann-Whitney U-test with multiple testing corrections and were confirmed with the SAM software. Selected gene lists (mean fold change .2 and FDR corrected P , 0.05) were submitted to Ingenuity software (http://www.ingenuity.com) to identify the biological mechanisms altered by these gene expression variations.
Predictor construction
This three-step process extensively described elsewhere (Rème et al., 2008) has been modified for paired samples. Affymatrix detection calls were used throughout with only two levels of expression, 'Present' as 1 and 'Else' as 0. As recommended by others (McClintick and Edenberg, 2006) , probe sets were filtered by selecting half the size of a sample class as the minimal number of present calls across all samples. Probe sets with poorly informative signals were further eliminated using a minimal variation coefficient of 40%, leading to a final 16 130 probe sets out of a 54 675 probe sets U133P chip.
Reduction of the data dimensionality was achieved by comparing each probe set distribution in sample groups considered as multiple drawings of a two-stage criterion (presence, 1; else, 0). Briefly, to account for the paired situations (LH2 and LH7) for one patient, a probe set vector was constructed whose values are either 0 if both situations lead to the Biomarkers of human endometrial receptivity same call or 1 if they differ. This vector is then compared with the null vector using a x 2 test, with a multiple testing corrected P-value resulting in a 200 -500 probe set list, subsequently used for supervised analysis.
The capacity of such a list to separate sample classes is evaluated as described previously by maximizing the significance of sample-to-sample comparisons using a x 2 test with the Bonferroni correction for multiple testing and the Yates correction for small sample numbers in two class comparisons. If the significance threshold is reached, the samples are not in the same class. This is repeated for comparison of each class sample paired to any sample of the other class and the initial number and strength of non-significant comparisons can be determined. Reducing the list is achieved by minimizing the number of non-significant comparisons by successive deletions of the probe set giving the best improvement. The process stops when no criterion can be further improved by probe set removal, the remaining list being the predictor. For leave-one-out cross-validation, each sample pair in turn is removed, and the whole process of dimensionality reduction and predictor building is run with the Bonferroni correction on the remaining samples as described for initial classes. Each predictor build in this way is tested for its capacity to generate misclassification errors when the omitted sample is returned to its class, where the number of non-significant comparisons should be 0.
Quantitative PCR analyses
Labeled cRNA (1 mg) from the patient was used to generate first-strand cDNA. These cDNAs (5 ml of a 1/10 dilution) were used for quantitative PCR reactions according to the manufacturer's recommendations (Applied Biosystems). The 20 ml reaction mixture consisted of cDNA (5 ml), 1 mM of primers and 10 ml of Taqman Universal PCR Master Mix (Applied Biosystem). The amplification was measured during 40 cycles with an annealing temperature at 608C. Phosphoglycerate kinase 1 was used to normalize expression levels between the samples.
Statistical analyses
Statistical analyses for quantitative PCR values were performed with the Microsoft Office Excel software. A difference of mean + SEM between sample groups was considered significant when Student's t-test gave a P-value of ,0.05.
Results
Gene expression profile as a function of endometrial receptivity Selection using a variation coefficient (40%) and the absent/present 'detection call' (presence in at least 15 samples) between LH þ 2 and LH þ 7 samples was first performed, delineating 16 200 probe sets, and then subjected to an unsupervised analysis with PCA (3000 probe sets) (Fig. 1A) . In this PCA, 80% of LH þ 7 samples were separated from the others using the first two dimensions, representing 16% of the data information (Fig. 1A) . A hierarchical clustering was performed with the same data (3000 probe sets) and confirmed the PCA analysis (Fig. 1B) . Then, we performed a SAM analysis between the LH þ 2 and the LH þ 7 sample groups (LH þ 2 versus LH þ 7, paired sample analysis). One thousand and twelve genes were significantly modulated between these two groups, including 945 up-regulated genes and 67 down-regulated genes in the LH þ 7 sample group (fold change 2 and P , 0.05). To identify new markers of endometrial receptivity, we have compared our gene list significantly modulated between the LH þ 2 and LH þ 7 sample groups with four other studies which compared the same natural endometrium cycle phases (Table I) (Carson et al., 2002; Riesewijk et al., 2003; Mirkin et al., 2005; Talbi et al., 2006) . There were only two genes in common with all these studies, 12 genes in four, 59 genes in three and 142 genes in two out of the five studies (including our study) (Fig. 2) .
Determination of genes specifically modulated during the implantation window
We identified a list of genes specifically modulated during the implantation window and exclusive to the current study (Fig. 2) . We performed a hierarchical clustering with the same data (797 genes). This list of genes allowed the separation of the two endometrium sample groups, and Fig. 3 illustrates this separation. Interestingly, the majority of these genes were up-regulated during the implantation window (746 up-regulated genes and 51 down-regulated genes).
Validation of the predictor list
We first performed a PCA analysis of our LH þ 2 and LH þ 7 samples with the predictor list (comprising 60 probe sets, as described in Materials and Methods) with a 6% leave-one-out cross-validation error for P 0.01. Seventy-five percentage of LH þ 7 samples were separated from the other samples in this PCA using the first two dimensions, representing 52% of the data information (Fig. 4A) . We then tested our predictor list on the Talbi et al. (2006) samples, which consisted of three early secretory samples and eight midsecretory samples. As shown in Fig. 4B , the PCA analysis of these Figure 1 Unsupervised classification with both PCA and hierarchical clustering of 62 endometrium samples during the early and the mid-secretory stages from a natural cycle. (A) Unsupervised analysis between samples was performed, allowing a separation between the two sample groups, 2 and 7 days after the LH surge (LH þ 2 and LH þ 7) using the first two dimensions. (B) A hierarchical clustering was performed with the same data and this confirmed the PCA analysis. independent samples with our predictor list allows a distinct separation using the first two dimensions between the two sample groups (LH þ 2 and LH þ 7), representing 53% of the data information.
Candidate gene selection of the implantation window
To select candidate genes of the implantation window, we have compared our list of genes specifically modulated during the implantation window and exclusive to our study with the list of predictor. We have selected four new genes predicting endometrial receptivity, not listed in previous reports of microarray analysis. These new markers are microfibril-associated protein 5 (MFAP5), angiopoietin-like 1 (ANGPTL1), endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and nuclear localized factor 2 (NLF2), and our microarray data show they are all over-expressed during the implantation window by a factor of 37, 12.6, 10.2 and 22.5, respectively. In addition, a gene found in two other microarray analyses (Riesewijk et al., 2003; Talbi et al., 2006) and in our study was chosen as a positive control of human endometrial receptivity. This gene is laminin b3 (LAMB3) and is over-expressed by a factor of 20.4 in our study, and a factor of 15 and 6.6 in the chosen articles (Table II) . To quantify expression of these genes, five LH þ 2 samples and five LH þ 7 samples were randomly selected from the original samples. Mean transcript levels were significantly higher in LH þ 7 samples for all selected genes when compared with LH þ 2 samples and were 0.8 + 0.2 versus 0.05 + 0.02 for LAMB3 (P ¼ 0.002), 7.3 + 2.9 versus 1.4 + 0.6 for ANGPTL1 (P ¼ 0.005), 67.4 + 28.1 versus 3.5 + 1.9 for MFAP5 (P ¼ 0.009), 3.9 + 2.6 versus 0.45 + 41 for EG-VEGF (P ¼ 0.049) and 0.9 + 0.4 versus 0.05 + 0.02 for NLF2 (P ¼ 0.007) (Fig. 5 ).
ICSI outcome and marker genes
After the second ICSI attempt, an ongoing pregnancy was obtained in 11 out of the 31 patients who were studied during the preceding natural cycle. The expression of our five genes did not differ between the pregnant and the non-pregnant patients, either in the LH þ 2 or LH þ 7 subgroups.
Discussion
A recent meta-analysis from Assou et al. (2007) found that among 38 original studies reporting the transcriptome of human embryonic stem cells, only one gene was identified in all studies. Therefore, we expected that, using a similar approach, there would be very few genes significantly and similarly regulated during the implantation window in all studies of the endometrium. Indeed, when adding our data to the previous studies (Carson et al., 2002; Riesewijk et al., 2003; Mirkin et al., 2005; Talbi et al., 2006) , only two up-regulated genes were found in common: secreted phosphoprotein 1 (SPP1) and interleukin 15 (IL15). Briefly, SPP1, also called osteopontin, is a glycoprotein involved in cellular adhesion and migration during embryo implantation. SPP1 is a ligand for avb3 integrin and its maximal expression has been observed in endothelial cells during the implantation window (von Wolff et al., 2001 cells. This cytokine seems to be involved in stages immediately before, during and after the apposition step and it permits adequate proliferation of the stroma (Lédée et al., 2007) . In addition, our microarray analysis identified a series of markers among which we selected five candidates-LAMB3, MFAP5, ANGPTL1, EG-VEGF and NLF2-that we validated by quantitative PCR. Interestingly, in the baboon endometrium, laminin expression is increased at the implantation site and throughout the endometrium, suggesting a role of this extracellular matrix (ECM) component in endometrial receptivity (Fazleabas et al., 1997) . On the other hand, MFAP5, also called MAGP2, was also over-expressed in our LH þ 7 sample group. This gene encodes a microfibril-associated glycoprotein which is a component of microfibrils, an important structural component of elastic tissues, such as vasculature. By interacting with both ECM, such as collagen, and cell-associated proteins, such as integrins, this protein is therefore positioned to potentially modulate cell-matrix interactions and to participate in cell signaling pathways (Lemaire et al., 2005; Miyamoto et al., 2006) . Moreover, it has been recently suggested that MFAP5 has a role in Notch signaling activation, a pathway involved in vascularization during embryogenesis, development and normal homeostasis (Shawber et al., 2003) .
We also found that two members of the VEGF family, EG-VEGF and ANGPTL1, were over-expressed in human endometrium during the implantation window. EG-VEGF, also called PROK1, is a newly identified angiogenic and permeability enhancing factor which is predominantly expressed in steroidogenic tissues. EG-VEGF is also expressed in the normal peri-implantation endometrial samples from patients of reproductive age, and rarely detected in the endometrial samples from post-menopausal patients and patients with endometrial carcinoma (Ngan et al., 2006) . EG-VEGF is predominantly expressed in the glandular epithelial cells, with a peak protein expression at the mid-luteal phase of the menstrual cycle (Torry et al., 1996; Kisliouk et al., 2003; Battersby et al., 2004; Ngan et al., 2006) . The coexistence of EG-VEGF and its receptor, PROKR1 (data not shown), in human endometrium supports the idea that EG-VEGF may regulate proliferation, angiogenesis and permeability and induce the formation of endothelial fenestration. ANGPTL1 is a member of the angiopoietin-related protein family. In in vitro studies, ANGPTL1 has anti-apoptotic activities through the phosphatidylinositol 3-kinase/Akt pathway and regulates angiogenesis (Johnson et al., 2006) . In the ovariectomized ewe model, ANGPTL1 mRNA is increased after E 2 treatment (Johnson et al., 2006) . In our study, we observed an over-expression of ANGPTL1 gene during the implantation window of endometrium, which was confirmed by quantitative PCR.
In our microarray data and quantitative PCR analysis, the NLF2 gene was strongly expressed in the LH þ 7 sample group, suggesting that it has a role in endometrium remodeling during the implantation window. Invasion into the endometrial stroma is facilitated by inflammation. NLF2 was recently identified as a nuclear factor and as a We have analyzed four studies and our study to identify common genes in these reports. There are very few genes that were significantly and similarly regulated during the implantation window: only two genes in common with all these studies, 12 genes in four, 59 genes in three and 142 genes in two out of the five studies. We then identified a list of genes specifically modulated during the implantation window and exclusive to our study. This list consists of 797 genes, including 746 up-regulated and 51 down-regulated genes. . The PCA analysis of these independent samples with our predictor list allows a distinct separation between the two sample groups.
Biomarkers of human endometrial receptivity member of a family of regulatory genes that play a role in endothelial cell inflammation (Warton et al., 2004) . Initially identified in a genomewide array screen of human microvascular endothelial cells treated with IL 1b, NLF2 is probably part of the signaling pathway causing changes in cell architecture and adhesion in endothelial cell inflammation (Warton et al., 2004) . Disparities with other findings (Carson et al., 2002; Riesewijk et al., 2003; Mirkin et al., 2005; Talbi et al., 2006) may be explained by several factors: type of microarrays used, data analysis, statistical methodologies, size of patient samples, age of subjects, patient fertility/infertility and sampling time during the cycle (Table I) . One possibility to explain why our five candidate genes were not identified by others is our choice to use new microarrays containing more genomic information (.30 000 genes for the Hu133P oligonucleotide microarrays versus 12 000 genes for the Hu95A used by others). Moreover, only Riesewijk et al. (2003) analyzed samples from the same patient in the early and the mid-secretory phase as was done in the present study, which is an important point to minimize inter-patient variability. Indeed, performing microarray analysis with paired samples-each patient was biopsied at LH þ 2 and LH þ 7-allowed us to minimize the impact of inter-patient variability on the data analysis. However, one of the most important differences from all reported studies was the number of patient samples (n 11 versus 62 in the present study). This seems to us important, knowing the changing behavior of the human menstrual cycle that causes significant inter-and intra-individual variability among a patient group.
Finally, we cannot exclude the possibility that the modulation of gene expression observed during the implantation window was the consequence of local injury caused by the first endometrial biopsy. Indeed, Barash et al. (2003) showed that multiple endometrium biopsies during the spontaneous menstrual cycle increased implantation and pregnancy rates in the following cycle of treatment, and more recently Kalma et al. (2008) reported that the first endometrial biopsy modulated a wide variety of genes in the same cycle as well as in the following cycle. Therefore, further investigations should be conducted to validate our biomarkers. In addition, for practical reasons, endometrial biopsies were only performed during a spontaneous cycle and therefore extrapolation of our data to cycles with IVF treatment still requires some caution.
In conclusion, our data using analysis of transcriptomic pattern of endometrium could open new perspectives, especially in patients with multiple implantation failures. Analysis of our list of genes could reveal an alteration of the endometrial expression profile for some normoresponder patients. The information given by these biomarkers during a natural cycle could then be used subsequently to adapt the IVF protocol in patients with poor implantation.
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